LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its competitors? We will compare LeMaitre Vascular to similar companies based on the strength of its dividends, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.
Analyst Recommendations
This is a summary of current ratings and recommmendations for LeMaitre Vascular and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| LeMaitre Vascular | 0 | 6 | 3 | 0 | 2.33 |
| LeMaitre Vascular Competitors | 4252 | 10480 | 18203 | 824 | 2.46 |
LeMaitre Vascular presently has a consensus target price of $110.60, suggesting a potential upside of 36.64%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 25.50%. Given LeMaitre Vascular’s higher possible upside, equities research analysts clearly believe LeMaitre Vascular is more favorable than its competitors.
Risk and Volatility
LeMaitre Vascular has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, LeMaitre Vascular’s competitors have a beta of 5.49, meaning that their average share price is 449% more volatile than the S&P 500.
Earnings and Valuation
This table compares LeMaitre Vascular and its competitors revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| LeMaitre Vascular | $249.60 million | $57.73 million | 28.40 |
| LeMaitre Vascular Competitors | $1.88 billion | $139.14 million | 10.75 |
LeMaitre Vascular’s competitors have higher revenue and earnings than LeMaitre Vascular. LeMaitre Vascular is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares LeMaitre Vascular and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| LeMaitre Vascular | 25.02% | 15.63% | 10.06% |
| LeMaitre Vascular Competitors | -278.23% | -150.07% | -21.87% |
Dividends
LeMaitre Vascular pays an annual dividend of $1.00 per share and has a dividend yield of 1.2%. LeMaitre Vascular pays out 35.1% of its earnings in the form of a dividend. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.2% and pay out 44.8% of their earnings in the form of a dividend. LeMaitre Vascular has raised its dividend for 14 consecutive years.
Institutional & Insider Ownership
84.6% of LeMaitre Vascular shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by insiders. Comparatively, 14.8% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
LeMaitre Vascular competitors beat LeMaitre Vascular on 8 of the 15 factors compared.
About LeMaitre Vascular
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient’s body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.
